Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Kelshikar S, et al
August 12 Product: Ascendis Pharmas Yorvipath Indication: Hypoparathyroidism After a long regulatory road, Ascendis Pharma received FDA approval Monday for Yorvipath (TransCon PTH) for the treatment of hypoparathyroidism, a rare endocrine disease characterized by abnormally low levels of the parathyroid hormone
Similarly, if you are unwell with vomiting or severe gastrointestinal symptoms, your GP may advise temporarily holding your injection
Its not all in your head
[13] [14] These ICH guidelines are cited here as general pharmaceutical-quality frameworks and do not by themselves establish regulatory specifications for research-use-only materials
US$ 27.47
US$ 22.65
US$ 29.79
US$ 25.23
US$ 25.86
US$ 24.54
US$ 23.41
US$ 26.20
